Acute Coronary Syndrome Clinical Trial
— NITRATE-CINOfficial title:
Effect of Inorganic Nitrate on Contrast-induced Nephropathy in Patients Undergoing Coronary Angiography/Percutaneous Coronary Intervention for Acute Coronary Syndrome (ACS): A Randomised Single-centre, Double-blind Placebo-controlled Trial
NCT number | NCT03627130 |
Other study ID # | 18/1 |
Secondary ID | |
Status | Completed |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | November 29, 2018 |
Est. completion date | May 30, 2022 |
Verified date | December 2022 |
Source | Barts & The London NHS Trust |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Contrast-induced nephropathy (CIN), an acute kidney injury resulting from the administration of intravascular iodinated contrast media, is an important cause of morbidity/mortality following coronary angiographic procedures in high-risk patients. Despite preventative measures intended to mitigate the risk of CIN, there remains a need for an effective intervention. Dietary inorganic nitrate therapy, which through its chemical reduction in the body delivers nitric oxide has shown promise in attenuating CIN, but its effectiveness in preserving long-term renal function is unknown.
Status | Completed |
Enrollment | 640 |
Est. completion date | May 30, 2022 |
Est. primary completion date | May 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility | Inclusion Criteria: 1. Patients undergoing coronary angiography+/-Percutaneous Coronary Intervention (PCI) for NSTE-ACS 2. Requirement for CIN prophylaxis as per Barts Heart Centre Criteria for CIN prophylaxis: eGFR<60ml/min OR 2 of the following: diabetes, liver failure (cirrhosis), age > 70yr, exposure to contrast in last 7 days, heart failure (or LVEF<40%), concomitant renally active drugs (ACEi, ARB, NSAIDs, aminoglycosides, diuretics) 3. Aged >18 4. Patients able and willing to give their written informed consent. Exclusion Criteria: 1. ST segment myocardial infarction undergoing Primary PCI. 2. Patients with eGFR<30ml/min or on renal replacement therapy 3. Subjects presenting with cardiogenic shock (systolic blood pressure <80 mmHg for >30 minutes, or requiring inotropes or emergency intra aortic balloon pump for hypotension treatment) or cardiopulmonary resuscitation 4. Current life-threatening condition other than vascular disease that may prevent a subject completing the study. 5. Use of an investigational device or investigational drug within 30 days or 5 half-lives (whichever is the longer) preceding the first dose of study medication. 6. Patients considered unsuitable to participate by the research team (e.g., due to medical reasons, laboratory abnormalities, or subject's unwillingness to comply with all study related procedures). 7. Severe acute infection 8. Pregnancy 9. Breast-feeding mothers. 10. Any Inclusion Criteria not met |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Barts Heart Centre | London |
Lead Sponsor | Collaborator |
---|---|
Barts & The London NHS Trust |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Contrast Induced Nephropathy | Defined by Kidney Disease: Improving Global Outcomes (KDIGO) criteria | 48-72 hours | |
Secondary | Demonstration of a persistent benefit of dietary inorganic nitrate against long-term renal impairment | Difference in real function as measured by eGFR (estimated glomerular filtration rate) at 3 months post-contrast exposure | 3 months | |
Secondary | Measurement of Circulating Nitrite and Nitrate levels | Plasma Nitrite/Nitrate levels | Baseline, and at 6 hours, 48 hours and 3 months following treatment. | |
Secondary | Major Adverse Cardiac Events | Defined as death, non-fatal myocardial infarction, revascularisation, acute heart failure, non-fatal stroke | 3 and 12 months follow-up | |
Secondary | Cost effectiveness of dietary inorganic Nitrate | Incremental Cost Effectiveness Ratio (ICER) | 1 year | |
Secondary | To determine if dietary inorganic nitrate ingestion decreases sub-clinical renal injury as measured by urinary renal biomarkers | Measurement of urinary IGFB7/TIMP-2 | 4-6 hours | |
Secondary | To determine if dietary inorganic nitrate ingestion decreases sub-clinical renal injury as measured by serum biomarkers | Measurement of serum Neutrophil gelatinase-associated lipocalin (NGAL) | 4-6 hours | |
Secondary | To determine if dietary inorganic nitrate decreases rates of post-procedural Myocardial Infarction | Definition as per Society for Cardiovascular Angiography and Interventions (SCAI) | 6-12 hrs |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06013813 -
Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT05412927 -
AngelMed Guardian® System PMA Post Approval Study
|
||
Completed |
NCT02750579 -
Early or Delayed Revascularization for Intermediate and High-risk Non ST-elevation Acute Coronary Syndromes?
|
N/A | |
Completed |
NCT04102410 -
Assessing Force-velocity Profile: an Innovative Approach to Optimize Cardiac Rehabilitation in Coronary Patients
|
N/A | |
Enrolling by invitation |
NCT03342131 -
Serum Concentration of Wnt2 and Wnt4 in Patients With Acute Coronary Syndrome
|
N/A | |
Recruiting |
NCT01218776 -
International Survey of Acute Coronary Syndromes in Transitional Countries
|
||
Enrolling by invitation |
NCT04676100 -
International CR Registry
|
||
Completed |
NCT03590535 -
5th Generation cTnT in ED ACS
|
||
Recruiting |
NCT05437900 -
INSIGHTFUL-FFR Clinical Trial
|
Phase 4 | |
Completed |
NCT05551429 -
Factors Related to Participation in Cardiac Rehabilitation in Patients With Acute Coronary Syndrome
|
||
Terminated |
NCT04316481 -
IDE-ALERTS Continued Access Study
|
N/A | |
Active, not recruiting |
NCT04475380 -
Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
|
||
Not yet recruiting |
NCT04852146 -
Electronic Feedback for Data Restitution and Valorization to the Emergency Teams in Aquitaine.
|
||
Active, not recruiting |
NCT02892903 -
In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes?
|
N/A | |
Completed |
NCT02944123 -
Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR)
|
Phase 3 | |
Not yet recruiting |
NCT02871622 -
BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM
|
N/A | |
Completed |
NCT04077229 -
Piloting Text Messages to Promote Positive Affect and Physical Activity
|
N/A | |
Active, not recruiting |
NCT02922140 -
The Impact of Pharmaceutical Care Practice on Patients in Cardiac Rehabilitation Unit
|
N/A | |
Completed |
NCT02673437 -
Rivaroxaban ACS Specialist Cohort Event Monitoring Study
|